Donaldson Company delivered a solid start to fiscal 2025 with total sales of $900.1 million, up 6% year over year, driven by volume growth across all three segments and modest pricing and currency benefits. The quarter showcased continued margin discipline, with gross margin of 35.6% and operating margin of 14.9%, supported by product mix and volume leverage. Management highlighted ongoing efficiency actions, including footprint optimization in Life Sciences, and a broader investment stance aimed at sustainable long-term profitability through capacity additions, new products, and strategic acquisitions.
Mobile Solutions led top-line growth via aftermarket share gains and expanded distribution capacity, Industrial Solutions benefited from strong Aerospace & Defense performance and rising connected solutions, while Life Sciences posted double-digit sales growth on Disk Drive and Food & Beverage strengths, albeit with a pre-tax loss driven by ramp costs in acquisitions. The balance sheet remains robust (net debt/EBITDA ≈ 0.6x), and the company reaffirmed a diligent capital deployment plan: capex of $85–$105 million, 85–95% cash conversion, and return of 2–3% of outstanding shares alongside a long-standing dividend track record. The guidance implies execution of a mid-single-digit top-line trajectory for the year with improving profitability as backlogs normalize, though Life Sciences profitability remains a key swing factor in the outlook.